The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     

 NuVasive Inc.  (NUVA) Trade Now »     Rate NUVA  -  Discuss NUVA  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Medical Equipment & Supplies
SocialPicks Sentiment:

** v.s. other stocks 		This Quarter's Sentiment:
All:
55.5%
Top:
0.0%
Rate NUVA:


Home
Analysis & Videos
Quotes
Bull or Bear
Discuss
        

NUVA: Bull or Bear? From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

NUVA $5 TO $10 Target Price...Extremely Overvalued By Valuation...Why? Graphic_rating_sell NUVA
69%
 +34.54%
in 425 days

NUVA is overvalued, looking only at valuation relative to its Industry.

* NUVA has a Projected P/E of 105.73 (huge)
* NUVA's Industry (Medical Instruments & Supplies) has an average Projected P/E of 22.32
* Implies a Projected Stock Price of $10.04

* NUVA has a projected earnings growth rate of 5.10%
* NUVA has a PEG of 20.73 (huge)
* NUVA's Industry (Medical Instruments & Supplies) has an average Projected PEG of 2.23
* Implies a Projected Stock Price of $5.12

Source of the analysis and calculations:

<> <> <>http://www.freestockvalueranker.com/...
By  energycurve   (+10.27%  risk: conservative)  10/05/08 2 comments


Bullish on NUVA ... Graphic_rating_buy NUVA
Puppy_250x251
16%
 -11.98%
in 684 days
(closed on 10/28/09)
<> "NuVasive [NUVA]. It isn't an inexpensive stock, but it's a very early-stage stock with revenue growth around 60% being driven by new products. They have a product used in minimally invasive spine fusion surgery and they have a number of products under development that are potentially very interesting. One is an artificial disk product. There is nice potential upside if it works out. In the meantime, they have a very solid spinal-fusion business, which is driving all of the current estimates and growth rate."

http://online.barrons.com/article/SB119525667524396310.html?m... ...
By  J Alex   (-17.50%  risk: moderate)  12/13/07 Comment


3Q07 Earnings & Color on Growth Graphic_rating_buy NUVA
N/A
 -30.58%
in 766 days

NUVA's 3Q results continue to demonstrate the revenue growth potential of the Company's product portfolio. Additionally, Management added color on 2008 sales growth potential of +35% y-o-y. While excellent news, I am inclined to agree with Lehman Brothers view that this number could prove conservative given the continued focus on expanding the sales force and the expected return from this investment to the revenue line. With this kind of growth story, a valuation premium to other medical device stocks is justified and should continue to support the valuation.

<> Given how far the stock ...
By  Allan S   (-12.47%  risk: aggressive)  10/30/07 Comment


Strong Demographics and Position Improvement in Spine Sector Graphic_rating_buy NUVA
N/A
 +18.93%
in 15 days
(closed on 10/30/07)
NUVA is continuing to post strong y-o-y results w/ solid double digit sales growth. Top line improvement has been driven by favorable demographic trends in spine, a highly accepted product portfolio, and movement toward a decicated, exclusive sales force.
By  Allan S   (-12.47%  risk: aggressive)  10/15/07 Comment




From the Blogosphere

NuVasive (NUVA) - When Momentum Begets Momentum
Tradermark
34%
This past week I've been looking around seeing what sort of stocks are consistent winners, and have seen a lot of names we've previously owned. One such name is NuVasive (NUVA) a smallish medical device maker which focuses mostly on the spine market.

<>
NuVasive, Inc., a medical device company, engages in the design, development, and marketing of products for the surgical treatment of spine disorders. Its products are used in applications for spine fusion surgery.


As I am trying to process how this market "works" in an increasingly computer dominated era, it seems momentum truly begets momentum...
By  Trader Mark   (-7.00%  risk: moderate)  06/22/09 Comment


The Meek Continue to Dominate Equities
Tradermark
34%
Early in April after a month long run off the bottom I posted a list of equities that gained at least 60% in the preceding 4 weeks [Apr 5: The Meek Shall Inherit the Earth: 92 Stocks Over $10 Returning 60%+] The list was a whose who of beaten down merchandise. Generally, by week 4-5 of an oversold rally these type of names begin to peter out but the ramp has been relentless in lower quality, low price stocks. My gut tells me quant (and other varieties) of hedge funds have been shorting these names, using fundamental reasons - expecting some pullback after huge runs - only to be run over ...
By  Trader Mark   (-7.00%  risk: moderate)  04/26/09 Comment


NuVasive (NUVA) Not for the Faint of Heart
Tradermark
34%
NuVasive (NUVA) is an interesting smallish cap medical device company I've followed for a long time. She is not for the feint of heart - and this stock's reaction around earnings season is why earnings are the best of times / worst of times for me. I love the new data points; I hate the raging stampede of lemmings over reacting. This chart alone shows you the "full round" trip you've encountered in the past 2 earnings reports - did business really change that much at all during this time? No. But if you were an unfortunate owner 3 months ago you were dismembered... or if you were a lucky...
By  Trader Mark   (-7.00%  risk: moderate)  04/27/09 Comment


Nuvasive (NUVA): Growth in adult stem cells Graphic_rating_buy NUVA
-1.15%
in 246 days

Filed under: Newsletters, Stocks to Buy

"In all the excitement over the new future for embryonic stem cell, it seems investors have forgotten about adult stem cell products," notes growth stock specialist Dave Dyer.

In his Dave Dyer's Newsletter, he explains, "In fact, there are adult stem cell products either already on the market or in late clinical trials. We view this as an excellent opportunity." Here, he looks at NuVasive (NASDAQ: NUVA).

<>"Stem cells can grow into any type of organ or tissue and the promise is that damaged organs may be repaired or even replaced with spare parts grown fro...
By  Steven Halpern   (+5.39%  risk: moderate)  04/03/09 Comment


Nuvasive (NUVA): Growth in adult stem cells
16%

"In all the excitement over the new future for embryonic stem cell, it seems investors have forgotten about adult stem cell products," notes growth stock specialist Dave Dyer.

In his Dave Dyer's Newsletter, he explains, "In fact, there are adult stem cell products either already on the market or in late clinical trials. We view this as an excellent opportunity." Here, he looks at NuVasive (NASDAQ: NUVA).

<>"Stem cells can grow into any type of organ or tissue and the promise is that damaged organs may be repaired or even replaced with spare parts grown from stem cells. This amazing potential...
By  The Stock Advisors   (-17.18%  risk: moderate)  04/02/09 Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.44% 381
2 Gerald Greene 18.14 +71.24% 211
3 stockmarketfunding.com 17.66 +25.60% 55
4 akiralegrand 13.47 +14.32% 62
5 anup2104 12.13 +74.22% 40


POPULAR STOCKS
Symbol Company Name Sentiment
XOM Exxon Mobil Corp
ETFC E*Trade Financial Corp
DRYS DryShips Inc.
PG The Procter & Gamble Company
F Ford Motor Company
V Visa Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 

StreetInsider.com on NUVA

Visit streetinsider.com


Discussion Wall + Add  
andrea   (-52.42%  risk: aggressive)
What do you think about NUVA and GSOL? - Good position for continued buying?
+   0 replies


More Resources

Graphic_arrow1 About NuVasive Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters




IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch